Uses of carbamoyl phosphate synthetase 1 (cps 1) and it's fragments for the diagnosis of liver diseases
AssigneeB.R.A.H.M.S GmbH
InventorsAndreas Bergmann, Joachim Struck, Monika Uhlein
Life of this patent
Estimating the term…
Abstract
Use of carbamoyl phosphate synthetase 1 (CPS 1) and/or of fragments of the N-terminal part of CPS 1 from body fluids or body tissues as marker peptides for the diagnosis and for the prognosis and the monitoring of inflammations and infections, including sepsis, and of liver failure as part of multiorgan failure or for determinations in connection with inflammatory and other liver diseases.
Claims9
1-17. (canceled)
A method for diagnosing a liver disease in a human patient comprising:
- (a) obtaining a blood, plasma, or serum sample from said patient;
- and
- (b) determining the presence and amount of human carbamoyl phosphate synthetase 1 (CPS 1) (SEQ ID NO:6) in said sample using an immunodiagnostic assay,
- wherein an elevated concentration of CPS 1 protein is indicative of liver disease.
The method of claim 23, wherein the antibodies are produced from a protein chosen from SEQ ID NO:7 and SEQ ID NO:8.
A method for detecting mitochondrial damage of the liver in a human patient comprising:
- (c) obtaining a blood, plasma, or serum sample from said patient;
- and
- (d) determining the presence and amount of human carbamoyl phosphate synthetase 1 (CPS 1) (SEQ ID NO:6) in said sample using an immunodiagnostic assay,
- wherein an elevated concentration of CPS 1 protein is indicative of mitochondrial damage of the liver.
Dependencies are inferred from the claim text.